January 30, 2013
Bart and Peter will discuss self-injection technology and the partnership between West and Janssen to develop the SelfDoseTM* injector platform technology.
West’s SelfDose system provides an integrated drug delivery solution designed to ease self-injection. Further, the integrated passive needle helps mitigate the risk of accidental needlestick injuries. The SelfDose system offers a convenient and easy-to-use solution for a wide range of drug products.
For more information or to register to attend the conference, visit: http://www.iirusa.com/ddp/agenda-at-a-%20Glance.xml.
*For investigational use only for our pharmaceutical and biotechnology development partners.
SelfDose™ is a trademark of West Pharmaceutical Services, Inc., in the United States and other jurisdictions. West seeks partners for its SelfDose™ injector technology platform. This platform is intended to be used as an integrated system with drug filling and final assembly completed by the pharmaceutical/biotechnology company.